At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jun 11, 2026 at 20:00 ET
HUTCHMED announced positive Phase 3 results for sovleplenib in warm AIHA (wAIHA), showing a 66% durable response rate vs 15% for placebo (p<0.0001). The NDA for wAIHA has been accepted and granted priority review by China's NMPA, and a separate resubmitted NDA for ITP also received priority review. These developments significantly strengthen sovleplenib's regulatory and commercial prospects in two indications with high unmet need.
- Phase 3 ESLIM-02 study met primary endpoint: durable response rate 66% for sovleplenib vs 15% for placebo (p<0.0001) in wAIHA patients.
- Overall response rate (Hb ≥100 g/L + ≥20 g/L increase without rescue) was 70% vs 22% (p<0.0001).
- Rescue therapy use reduced to 16% (sovleplenib) vs 54% (placebo); RBC transfusions reduced to 11% vs 43%.
- Median time to response was 3.1 weeks for sovleplenib vs 6.3 weeks for placebo.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access